HERO Phase 3 Trial Results: Relugolix vs. Leuprolide for Prostate Cancer

The HERO study compared the efficacy of oral GnRH receptor antagonist, Relugolix, with the commonly used ADT, Leuprolide Acetate, in treating advanced prostate cancer. Results showed that Relugolix achieved sustained castration more effectively than Leuprolide, with superior testosterone suppression

0 views • 29 slides